WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 4-6 in Boston. Olivier Loeillot, President and Chief Executive Officer will participate in an analyst-led discussion on Friday, September 6, at 8:45 a.m. ET.
A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com


Đề xuất
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
electroCore to Present at the Market Movers Investor Summit on May 5, 2026
Proxygen Expands Platform Beyond Degradation to Build Next-Generation Induced Proximity Therapeutics
Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity
Ping An Reports Steady 7.6% Growth in Operating Profit Attributable to Shareholders of the Parent Company in Q1 2026, Life & Health NBV Increases 20.8% YoY